Phanes Therapeutics, Inc.

Phanes Therapeutics, Inc.

Biotechnology Research

San Diego, California 2,093 followers

At Phanes, we bring innovation that illuminates the path to cure.

About us

Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, PT199, the TWINPEAK study with PT886 and the SKYBRIDGE study with PT217. Both PT886 and PT217 are first-in-class bispecific antibodies and have been granted orphan drug designation as well as Fast Track designation by the FDA. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer. For more information about Phanes Therapeutics, please visit www.phanesthera.com. For business development or media inquiries, please contact bd@phanestx.com or media@phanestx.com respectively.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
San Diego, California
Type
Privately Held
Founded
2016

Locations

  • Primary

    11535 Sorrento Valley Rd

    Suite 400

    San Diego, California 92121, US

    Get directions

Employees at Phanes Therapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding